Citius Oncology (CTOR) Projected to Post Quarterly Earnings on Friday

Citius Oncology (NASDAQ:CTOR) is anticipated to issue its results before the market opens on Friday, February 13th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.

Citius Oncology (NASDAQ:CTOR) last announced its earnings results on Tuesday, December 23rd. The company reported ($0.06) EPS for the quarter, meeting analysts’ consensus estimates of ($0.06).

Citius Oncology Stock Performance

NASDAQ:CTOR opened at $1.11 on Friday. The company has a quick ratio of 0.11, a current ratio of 0.56 and a debt-to-equity ratio of 0.08. The firm’s fifty day simple moving average is $1.14 and its 200 day simple moving average is $1.53. The stock has a market cap of $97.99 million, a P/E ratio of -3.26 and a beta of 3.09. Citius Oncology has a twelve month low of $0.55 and a twelve month high of $6.19.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Oncology in a research note on Monday, December 22nd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $6.00.

Institutional Trading of Citius Oncology

A number of hedge funds have recently modified their holdings of CTOR. Geode Capital Management LLC boosted its holdings in Citius Oncology by 179.0% in the second quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock worth $249,000 after acquiring an additional 36,758 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Citius Oncology in the 2nd quarter worth about $465,000. Bank of America Corp DE boosted its stake in Citius Oncology by 5,256.9% in the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock worth $37,000 after purchasing an additional 8,411 shares in the last quarter. Citadel Advisors LLC bought a new position in Citius Oncology in the 3rd quarter worth about $36,000. Finally, Armistice Capital LLC purchased a new stake in Citius Oncology during the 3rd quarter valued at about $15,582,000. Institutional investors own 70.52% of the company’s stock.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.